NextCell Pharma

NextCell Pharma EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of NextCell Pharma (NXTCL.ST) as of Oct 24, 2026 is -46.75 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -53.11 % — a change of -11.98% (higher).

EBIT/Assets

-46.75 %

YoY

-11.98%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of NextCell Pharma is 2025 -46.75 % . Operating Income to Assets Ratio (EBIT/Assets) of NextCell Pharma was 2024 -53.11 % . It decreases by -11.98% higher compared to the previous year.

The NextCell Pharma EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
-165.06 SEK
Jan 1, 2019
-80.30 SEK
Jan 1, 2020
-59.46 SEK
Jan 1, 2021
-15.95 SEK
Jan 1, 2022
-28.10 SEK
Jan 1, 2023
-46.16 SEK
Jan 1, 2024
-53.11 SEK
Jan 1, 2025
-46.75 SEK
The NextCell Pharma EBIT/Assets history
YEAREBIT/AssetsYoY
-46.75 %-11.98%
-53.11 %+15.06%
-46.16 %+64.29%
-28.10 %+76.16%
-15.95 %-73.17%
-59.46 %-25.96%
-80.30 %-51.35%
-165.06 %+169.19%
-61.32 %-49.20%
-120.71 %+43.15%
-84.32 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

NextCell Pharma Stock analysis

What does NextCell Pharma do? NextCell Pharma AB develops stem cell therapies using a proprietary selection algorithm, focusing on autoimmune diabetes and other autoimmune diseases. The company operates a tissue establishment and biobank as a healthcare provider, commercializing mesenchymal stem cell products. Its primary revenue comes from the development and sale of these stem cell therapies to healthcare institutions and research organizations. The firm's business model centers on R&D for stem cell products, with the tissue establishment and biobank supporting its research activities. NextCell targets healthcare providers and research entities as key customers for its stem cell therapies and biobank services. NextCell Pharma AB's revenue streams are derived from the commercialization of its stem cell therapies, leveraging its proprietary technology for autoimmune disease treatment. The company's focus on mesenchymal stem cell products positions it within the healthcare provider segment, specifically serving institutions requiring advanced cell-based treatments. NextCell Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NextCell Pharma stock

Operating Income to Assets Ratio (EBIT/Assets) of NextCell Pharma is -46.75 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of NextCell Pharma changed from -53.11 % to -46.75 %, representing a -11.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) NextCell Pharma since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s NextCell Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — NextCell Pharma

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — NextCell Pharma